Nycomed: Changing (Private) Hands

Closed public markets didn't stop private equity group Nordic Capital from selling its investment in Denmark's Nycomed for a tidy profit. CSFB Private Equity and a group of other investors paid more than $1 billion for a firm they believe has plenty of growth potential yet.

Buy-outs are the latest fashion in the health care industry. With public markets closed, private equity groups are looking to put large amounts of capital to work in companies that can survive without continued access to new money. In pharmaceuticals, the opportunities have never been better: drug companies are willing to sell off what they consider peripheral businesses which nonetheless may be generating substantial cash flows. Meanwhile, pharmaceutical valuations are at record lows. Buy-outs, in short, are available and look cheap—and thus even players who have done only sporadic pharmaceutical investing are coming into the market. Earlier this year, for example, Advent Partners bought Viatris--the remains of Asta Medica's pharmaceutical business--for €375 million ($347 million), in the largest pharmaceutical buyout [See Deal]. (See "Viatris: Shedding the Past," In Vivo Europe Rx, October 2002 [A#2002600073].)

But the estimated $1.1-1.3 billion stumped up by CSFB Private Equity, The Blackstone Group and NIB Capital Private Equity for...

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By 

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.